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We report a case of a 14-year-old boy who initially suffered from a sudden onset of abdominal pain for
2 weeks with a protrusive soft mass over the left upper abdomen. No obvious symptomatic symptoms or
body weight loss were observed. However, early lung metastasis was detected after an initial computed
tomographic examination. Even after we performed salvage en bloc resection of the huge retroperitoneal
tumor after primary neoadjuvant chemotherapy, the ﬁnal outcome was still poor. A diagnosis according
to radiologic ﬁndings was uncharacteristic. Finally, a pathologic diagnosis based on histologic and
immunohistochemical results revealed a rare renal peripheral primitive neuroectodermal tumor.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
A primitive neuroectodermal tumor is one of a remarkable
group of tumors that originate in cells from the primitive neural
crest, share the same reciprocal translocation between chromo-
somes 11 and 22, and show the same patterns of biochemical and
oncogenic expressions. Some primitive neuroectodermal tumors
occur in the brain while others [peripheral primitive neuro-
ectodermal tumors (PNETs)] occur at sites outside the brain such as
in the extremities, pelvis, chest wall, and retroperitonium. Here, we
present a case of a 14-year-old boy with a renal PNET and lung
metastases.
2. Case report
A 14-year-old boy suffered from a sudden onset of abdominal
pain for 2 weeks. A physical examination showed a protrusive soft
mass over the left upper abdomen with tenderness. Besides a poor
appetite recently, he denied fever, vomiting, diarrhea, or body
weight loss. The abdominal echo revealed a huge mass of about
16.717.1 cm in the left retroperitonium. Abdomen computedartment of Surgery, Chi Mei
ainan County 710, Taiwan.
en).
ciation. Published by Elsevier Taiwtomography (CT) showed a huge renal tumor with suspicion of
direct invasion of the spleen, pancreas body, and tail (Fig. 1) in
combinationwith lung metastases (Fig. 2). Under the impression of
a left huge renal tumor with multiple lungmetastases, an incisional
biopsy of the left renal tumor was done, and the pathology revealed
a PNET. Initially, the patient received neoadjuvant treatment
according to the protocol consisting of vincristine, actinomycin D,
ifosfamide, and adriamycin beginning on January 2, 2007. There-
after, treatment was shifted to a VAI (vincristine, actinomycin D,
and ifosfamide) regimen until March 2007. However, an abdominal
CT on May 4, 2007 after four cycles of VAI revealed an increasing
size of the renal tumor. Because the VAI protocol had a poor effect,
chemotherapy was then shifted to VIP (vincristine, ifosfamide, and
cisplatin). After two cycles of VIP chemotherapy, the bilateral lung
lesions regressed (Fig. 3), and partial regression of the left renal
PNET (Fig. 4) was noted on a follow-up CT scan in June 2007. Finally,
we performed salvage en bloc resection of the huge retroperitoneal
tumor after primary neoadjuvant chemotherapy. The operative
ﬁndings showed a huge retroperitoneal tumor with severe adhe-
sion to the retroperitoneal space. Grossly, the tumor of
1219 20 cm was located over the upper pole of the left kidney
(Fig. 5), and heterogeneous and cystic components with blood clots
were also noted. The pathology showed a highly speciﬁc cluster of
differentiated CD 99 (Fig. 6), and the special stain ﬁnally conﬁrmed
the diagnosis of PNET. Postoperatively, the patient receivedan LLC. Open access under CC BY-NC-ND license.
Fig. 1. Abdominal computed tomographic scan showing a huge mass
(19.518.8 11.8 cm) arising from the left kidney, with central necrosis.
Fig. 2. Small nodules over the bilateral lung ﬁeld suspected of being lung metastasis
(arrow).
Fig. 3. Normal bilateral lung parenchyma. No evidence of lymphoadenopathy of
>1 cm.
Fig. 4. Partial regression of the left renal primitive neuroectodermal tumor and tumor
size shrinkage to 16.515 9.7 cm.
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carboplatin, and irinotecan/temozolomide protocol for palliative
treatment. Unfortunately, the disease progressed and was
combined with complications of chemotherapeutic toxicity, septic
shock, and Klebsiella pneumoniae. Thereafter, multiple liver and
lung metastases and even brain metastases with intracranial
bleeding developed. Finally, the patient’s condition went downhill,
and he died due to chemotherapeutic toxicity and his poor physical
condition in January 2008.
3. Discussion
PNETs, ﬁrst recognized by Stout1 in 1918, are members of the
family of small round-cell tumors. The differential diagnosis of
PNETs includes lymphomas, neuroblastomas, Ewing’s sarcoma,Fig. 5. A huge renal tumor (1219 20 cm) growth in the upper pole of the kidney
with heterogeneous components and cystic components with blood clots (arrow).
Fig. 6. Tumor cells diffusely and strongly positive for CD99 in a membranous
pattern (200).
Fig. 7. HomereWright-type rosettes (arrow), a typical histological feature of primitive
neuroectodermal tumors and CD117 staining in a combined cytoplasmic and
membranous pattern (400).
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chymal chondrosarcomas, and undifferentiated carcinomas.2 They
tend to be grayish and encapsulated, and contain focal areas of
hemorrhage and or necrosis. PNETs of the kidney are extremely rare
disease entities and are morphologically and immunophenotypi-
cally indistinct from extrarenal PNETs.3 They show the same gene
fusion4 and have similar poor outcomes.
They frequently arise during childhood or adolescence.
HomereWright-type rosettes (Fig. 7), less deﬁned in extraskeletal
Ewing’s sarcoma, are a typical histological feature of PNETs and
can direct the diagnosis although they are also found in
neuroblastomas.5
To date, there is no absolute protocol or treatment for PNETs
owing to their rarity. Most reported cases underwent a radical
nephrectomy, adjuvant chemotherapy (vincristine, ifosfamide,
doxorubicin, cyclophosphamide, and etoposide), radiotherapy, or
a bone marrow transplant. The literature suggests a chemothera-
peutic protocol for PNETs consisting of four CEVAIE cycles, each
including three 3-week courses: CEV (500 mg/m2 carboplatin,
150 mg/m2 epirubicin, and 1.5 mg/m2 vincristine); IVA (9 g/m2
ifosfamide, 1.5 mg/m2 actinomycin, and 1.5 mg/m2 vincristine); and
IVE (9 g/m2 ifosfamide, 600 mg/m2 etoposide, and 1.5 mg/m2
vincristine).6 However, the outcome of PNET remains poor despite
these therapies. Thyavihally et al7 reported 60% and 42% survival
rates at 3 and 5 years, respectively. PNETs are considered very
aggressive tumors, but the advent of effective multimodality
therapy has improved the prognosis over time, and 5-year survival
is reported to be around 60%. Unfortunately, survival in patients
with metastatic disease at diagnosis has not improved despite
aggressive treatment.8
In this case, preoperative neoadjuvant chemotherapy in the ﬁrst
stage of treatment was mandatory to avoid a mutilating surgical
procedure and to diminish the risk of disseminating tumor
cells intraoperatively. Lung metastases showed dramatic total
regression, and the tumor size shrank after two cycles of chemo-
therapy with VIP. Unfortunately, the postoperative death was
caused by chemotherapeutic toxicity and some complications
induced by his poor general condition.4. Conclusions
Renal PNETs are rare. Differentiation of small round-cell tumors
of the kidney may be challenging, and asymptomatic lesions in this
location are often detected only by chance. Multimodal treatment
protocols combining tumor debulking, chemotherapy, and radio-
therapy may be useful for initial treatment, but the ultimate
disease-free survival is still poor.Conﬂicts of interest statement
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